Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) Stock Competitors & Peer Comparison
See CELG-RI's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CELG-RI and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CELG-RI | $0.10 | -8.10% | 206.3M | N/A | N/A | N/A |
| LLY | $1,231.58 | +3.87% | 1.2T | 39.10 | $31.49 | +0.53% |
| JNJ | $261.81 | +0.99% | 630.6B | 24.39 | $10.73 | +2.02% |
| ABBV | $247.91 | +0.76% | 437.9B | 24.32 | $10.19 | +2.78% |
| MRK | $130.90 | +1.80% | 323.3B | 40.78 | $3.21 | +2.57% |
| NVS | $156.79 | +0.29% | 298B | 18.04 | $8.69 | +3.03% |
| AZN | $161.91 | +0.30% | 251.1B | 17.48 | $9.26 | +1.29% |
| AMGN | $417.20 | +3.05% | 221.8B | 18.37 | $22.37 | +2.37% |
| NVO | $47.73 | +0.99% | 212B | 11.87 | $4.02 | +3.81% |
| GILD | $133.06 | -0.11% | 165.2B | -341.18 | -$0.39 | +2.42% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
CELG-RI vs LLY Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while LLY trades at $1,231.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas LLY's P/E ratio is 39.10. In terms of profitability, CELG-RI's ROE is N/A, compared to LLY's ROE of +0.93%. Regarding short-term risk, CELG-RI is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
CELG-RI vs JNJ Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, JNJ has a market cap of 630.6B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while JNJ trades at $261.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas JNJ's P/E ratio is 24.39. In terms of profitability, CELG-RI's ROE is N/A, compared to JNJ's ROE of +0.26%. Regarding short-term risk, CELG-RI is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
CELG-RI vs ABBV Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, ABBV has a market cap of 437.9B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while ABBV trades at $247.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas ABBV's P/E ratio is 24.32. In terms of profitability, CELG-RI's ROE is N/A, compared to ABBV's ROE of -1.37%. Regarding short-term risk, CELG-RI is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
CELG-RI vs MRK Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, MRK has a market cap of 323.3B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while MRK trades at $130.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas MRK's P/E ratio is 40.78. In terms of profitability, CELG-RI's ROE is N/A, compared to MRK's ROE of +0.07%. Regarding short-term risk, CELG-RI is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check MRK's competition here
Novartis AG (NYSE: NVS)
CELG-RI vs NVS Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, NVS has a market cap of 298B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while NVS trades at $156.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas NVS's P/E ratio is 18.04. In terms of profitability, CELG-RI's ROE is N/A, compared to NVS's ROE of +0.30%. Regarding short-term risk, CELG-RI is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
CELG-RI vs AZN Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, AZN has a market cap of 251.1B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while AZN trades at $161.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas AZN's P/E ratio is 17.48. In terms of profitability, CELG-RI's ROE is N/A, compared to AZN's ROE of +0.22%. Regarding short-term risk, CELG-RI is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
CELG-RI vs AMGN Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, AMGN has a market cap of 221.8B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while AMGN trades at $417.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas AMGN's P/E ratio is 18.37. In terms of profitability, CELG-RI's ROE is N/A, compared to AMGN's ROE of +0.89%. Regarding short-term risk, CELG-RI is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
CELG-RI vs NVO Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, NVO has a market cap of 212B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while NVO trades at $47.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas NVO's P/E ratio is 11.87. In terms of profitability, CELG-RI's ROE is N/A, compared to NVO's ROE of +0.59%. Regarding short-term risk, CELG-RI is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
CELG-RI vs GILD Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, GILD has a market cap of 165.2B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while GILD trades at $133.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas GILD's P/E ratio is -341.18. In terms of profitability, CELG-RI's ROE is N/A, compared to GILD's ROE of -0.16%. Regarding short-term risk, CELG-RI is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
CELG-RI vs PFE Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, PFE has a market cap of 154.2B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while PFE trades at $27.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas PFE's P/E ratio is 8.87. In terms of profitability, CELG-RI's ROE is N/A, compared to PFE's ROE of +0.05%. Regarding short-term risk, CELG-RI is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
CELG-RI vs BMY Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, BMY has a market cap of 132.5B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while BMY trades at $64.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BMY's P/E ratio is 10.94. In terms of profitability, CELG-RI's ROE is N/A, compared to BMY's ROE of +0.47%. Regarding short-term risk, CELG-RI is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check BMY's competition here
GSK plc (NYSE: GSK)
CELG-RI vs GSK Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, GSK has a market cap of 104.6B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while GSK trades at $52.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas GSK's P/E ratio is 11.27. In terms of profitability, CELG-RI's ROE is N/A, compared to GSK's ROE of +0.24%. Regarding short-term risk, CELG-RI is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check GSK's competition here
Sanofi (NASDAQ: SNY)
CELG-RI vs SNY Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, SNY has a market cap of 104.4B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while SNY trades at $43.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SNY's P/E ratio is 9.47. In terms of profitability, CELG-RI's ROE is N/A, compared to SNY's ROE of +0.06%. Regarding short-term risk, CELG-RI is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check SNY's competition here
Zoetis Inc. (NYSE: ZTS)
CELG-RI vs ZTS Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, ZTS has a market cap of 31.4B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while ZTS trades at $74.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas ZTS's P/E ratio is 11.37. In terms of profitability, CELG-RI's ROE is N/A, compared to ZTS's ROE of +0.69%. Regarding short-term risk, CELG-RI is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check ZTS's competition here
Biogen Inc. (NASDAQ: BIIB)
CELG-RI vs BIIB Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, BIIB has a market cap of 30.6B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while BIIB trades at $207.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BIIB's P/E ratio is 13.08. In terms of profitability, CELG-RI's ROE is N/A, compared to BIIB's ROE of +0.05%. Regarding short-term risk, CELG-RI is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
CELG-RI vs HZNP Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas HZNP's P/E ratio is 61.86. In terms of profitability, CELG-RI's ROE is N/A, compared to HZNP's ROE of +0.11%. Regarding short-term risk, CELG-RI is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
CELG-RI vs GRFS Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while GRFS trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas GRFS's P/E ratio is 9.25. In terms of profitability, CELG-RI's ROE is N/A, compared to GRFS's ROE of +0.08%. Regarding short-term risk, CELG-RI is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
CELG-RI vs OGN Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while OGN trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas OGN's P/E ratio is 4.07. In terms of profitability, CELG-RI's ROE is N/A, compared to OGN's ROE of +0.23%. Regarding short-term risk, CELG-RI is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check OGN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
CELG-RI vs CTOR Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, CTOR has a market cap of 70.2M. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while CTOR trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CTOR's P/E ratio is -1.61. In terms of profitability, CELG-RI's ROE is N/A, compared to CTOR's ROE of -0.99%. Regarding short-term risk, CELG-RI is more volatile compared to CTOR. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLXW)
CELG-RI vs SCLXW Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, SCLXW has a market cap of 58.9M. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while SCLXW trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, CELG-RI's ROE is N/A, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, CELG-RI is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check SCLXW's competition here
Scilex Holding Company (NASDAQ: SCLX)
CELG-RI vs SCLX Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, SCLX has a market cap of 56.8M. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while SCLX trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SCLX's P/E ratio is -0.17. In terms of profitability, CELG-RI's ROE is N/A, compared to SCLX's ROE of +1.90%. Regarding short-term risk, CELG-RI is more volatile compared to SCLX. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check SCLX's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
CELG-RI vs MIRA Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, MIRA has a market cap of 32.2M. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while MIRA trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas MIRA's P/E ratio is -0.53. In terms of profitability, CELG-RI's ROE is N/A, compared to MIRA's ROE of -1.41%. Regarding short-term risk, CELG-RI is more volatile compared to MIRA. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
CELG-RI vs BDSIW Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, CELG-RI's ROE is N/A, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, CELG-RI is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
CELG-RI vs CRXT Comparison August 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 206.3M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.10 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CRXT's P/E ratio is -0.02. In terms of profitability, CELG-RI's ROE is N/A, compared to CRXT's ROE of -4.63%. Regarding short-term risk, CELG-RI is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check CRXT's competition here